Article
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Hepatology (Baltimore, Md.) - 1 Mar 2012
Chayama Kazuaki, Takahashi Shoichi, Toyota Joji, Karino Yoshiyasu, Ikeda Kenji, Ishikawa Hiroki, Watanabe Hideaki, McPhee Fiona, Hughes Eric, Kumada Hiromitsu
Abstract excerpt
UNLABELLED: Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide and the most difficult to treat; genotype 1b is the most common subtyp...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.